Durvalumab vs Nitroglycerin
Durvalumab vs Nitroglycerin: Overview
This comparison examines the pharmacological differences between Durvalumab and Nitroglycerin.
Mechanism of Action
Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.
Nitroglycerin: Nitric oxide donor causing venous and arterial vasodilation.
Pharmacokinetics
Half-life: Durvalumab β 17 days; Nitroglycerin β 1-4 minutes.
Chemical Properties
Molecular Formula: Nitroglycerin β C3H5N3O9.
Molecular Weight: Nitroglycerin β 227.0870 g/mol.
Type: Durvalumab β Antibody; Nitroglycerin β Small molecule.